Paq Therapeutics, Inc.
Clinical trials sponsored by Paq Therapeutics, Inc., explained in plain language.
-
New cancer drug targets KRAS mutations in first human trial
Disease control Recruiting nowThis is the first human study of an experimental drug called PT0511 for people with advanced solid tumors that have specific KRAS genetic changes. The main goals are to find safe doses and see how the body processes the drug, both alone and combined with another cancer medication…
Phase: PHASE1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
First patients to receive experimental drug targeting common cancer mutation
Disease control Recruiting nowThis is the first human study of an experimental drug called PT0253 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goal is to find the safest dose and see how well the drug is tolerated in 115 participants. Researchers will al…
Phase: PHASE1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC